Medicine | Oncology
Prostate cancer
Treatment
Castration-sensitive (Castration-naive) prostate cancer


Home > Disciplines > Medicine > Oncology > Prostate cancer > Treatment > CSPC




Metastatic and Non-metastatic castration-sensitive


.

Sun G, Zhang X, Chen J, Liao B, Liu Z, Zhao J, Gao AC, Yang Y, Shu K, Liu J, Zhao P, Shen P, Zeng H.
What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis.
Urol Oncol. 2018 Oct 10. pii: S1078-1439(18)30344-2. doi: 10.1016/j.urolonc.2018.09.005. [Epub ahead of print]
Source | Full text | Similar articles



Metastatic castration-sensitive (mCSPC, M1)




OVERVIEW


.

Hamilou Z, Baciarello G, Fizazi K.
Treatment of Castration-naive Metastatic Prostate Cancer.
Eur Urol Focus. 2017 Dec;3(6):518-521. doi: 10.1016/j.euf.2018.02.004. Epub 2018 Feb 27.
Source | Full text | Similar articles



.

Saad F.
Continuing to improve outcomes of men with metastatic prostate cancer.
Nat Rev Clin Oncol. 2019 Jul 16. doi: 10.1038/s41571-019-0254-9. [Epub ahead of print]
Source | Full text | Similar articles



IDENTIFY MEN MORE LIKELY TO BENEFIT


.

Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C.
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
Eur Urol. 2018 Jun;73(6):847-855. doi: 10.1016/j.eururo.2018.02.001. Epub 2018 Feb 21.
Source | Full text | Similar articles



PREDICTION OF TIME TO HORMONAL TREATMENT FAILURE


.

Jadvar H, Velez E, Desai B, Ji L, Colletti PM, Quinn DI.
Prediction of time to hormonal treatment failure in metastatic castrate-sensitive prostate cancer with 18F-FDG PET/CT.
J Nucl Med. 2019 Mar 29. pii: jnumed.118.223263. doi: 10.2967/jnumed.118.223263. [Epub ahead of print]
Source | Full text | Similar articles



ENZALUTAMIDE WITH STANDARD FIRST-LINE THERAPY



Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.
Source . Similar articles



Non-Metastatic castration-sensitive (non-mCSPC, M0)




.

Fang D, Zhou L.
Androgen deprivation therapy in nonmetastatic prostate cancer patients: Indications, treatment effects, and new predictive biomarkers.
Asia Pac J Clin Oncol. 2019 Feb 6. doi: 10.1111/ajco.13108. [Epub ahead of print]
Source | Full text | Similar articles